Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

Abstract Background Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal a...

Full description

Bibliographic Details
Main Authors: Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Cancer
Subjects:
Renal carcinoma
Bevacizumab
Pazopanib
Combination Angiogenesis
Phase I trial
Online Access:http://link.springer.com/article/10.1186/s12885-017-3527-7

Internet

http://link.springer.com/article/10.1186/s12885-017-3527-7

Similar Items